Oncolytic immunotherapy and bortezomib synergy improves survival of refractory multiple myeloma in a preclinical model.
Thirukkumaran CM, Shi ZQ, Nuovo GJ, Luider J, Kopciuk KA, Dong Y, Mostafa AA, Thakur S, Gratton K, Yang A, Chin AC, Coffey MC, Jimenez-Zepeda VH, Stewart D, Chesi M, Bergsagel PL, Morris D.
Thirukkumaran CM, et al. Among authors: gratton k.
Blood Adv. 2019 Mar 12;3(5):797-812. doi: 10.1182/bloodadvances.2018025593.
Blood Adv. 2019.
PMID: 30850386
Free PMC article.